Almost everyone has been impacted by cancer, either personally or through a loved one, which is why we’re passionate about changing the status quo. Our commitment to saving lives drives us to explore approaches that haven’t been tried–or even thought of–before.
Aprea Therapeutics, Inc. (Nasdaq: APRE) is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers.
Scientific curiosity pushes Aprea to discover potential breakthroughs designed to address the significant unmet therapeutic needs of patients with certain genetically defined cancers. Our teams wake every day focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is APR-1051, a small molecule WEE1 inhibitor being developed for solid tumor indications. APR-1051 is in an ongoing Phase 1 study and has already demonstrated early clinical proof-of-concept.
Over a decade ago, our team was one of the first to recognize the DDR gene, ATR, as a potential target for precision cancer therapeutics. And we continue to forge new paths. Today, Aprea Therapeutics is a clinical-stage biotechnology company focused on the development of novel, synthetic lethality-based therapies with direct on-target mechanisms of action and clear clinical pathways.
Join us in our quest to develop cutting-edge cancer therapies designed to improve survival and quality of life while reviving patients’ hopes of pursuing their dreams.
3805 Old Easton Rd
Doylestown, PA 18902
Copyright © 2026 Aprea Therapeutics. All Rights Reserved.